Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Okay. Good morning. Thanks for joining us here at the JPMorgan Healthcare Conference. My name is Chris Cooper. I cover Australian health care here at JPMorgan. For this session, we're very fortunate to be joined by Christian Behrenbruch, the CEO of Telix.
Chris will speak for about 20 minutes or so, and we should have some time for Q&A at the end.
Well, thanks very much, Chris, and to the JPMorgan team for the opportunity to present. Just the customary disclaimers and forward-looking statements. So for those of you who don't know, and we're an increasingly well-known company in the radiopharma space. I know there's a lot of folks that are starting to take interest in the company and its commercial trajectory.
We're a fairly vertically integrated radiopharma company specializing in oncology. We are solely focused on radiopharmaceuticals. We have a very much a precision medicine-oriented
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
